MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy in Treating Patients With Sarcoma

Early Phase 1
Completed
Conditions
Ovarian Cancer
Sarcoma
First Posted Date
2008-04-21
Last Posted Date
2018-10-09
Lead Sponsor
Mayo Clinic
Target Recruit Count
28
Registration Number
NCT00662233
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Gemtuzumab ozogamicin
Drug: Mitoxantrone
Drug: Etoposide
First Posted Date
2008-04-17
Last Posted Date
2016-01-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
5
Registration Number
NCT00660036
Locations
🇺🇸

University of Pittsburgh Cancer Institute / Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Phase 3
Completed
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor
Interventions
Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Methotrexate
Drug: Thiotepa
Drug: Vincristine Sulfate
First Posted Date
2008-04-04
Last Posted Date
2024-04-23
Lead Sponsor
Children's Oncology Group
Target Recruit Count
70
Registration Number
NCT00653068
Locations
🇺🇸

Prisma Health Richland Hospital, Columbia, South Carolina, United States

🇺🇸

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

🇺🇸

Lee Memorial Health System, Fort Myers, Florida, United States

and more 91 locations

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Phase 1
Active, not recruiting
Conditions
Lymphoma
Interventions
Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Other: pharmacological study
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
First Posted Date
2008-03-24
Last Posted Date
2024-02-22
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
25
Registration Number
NCT00641381
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia
Interventions
Drug: mitoxantrone hydrochloride
Drug: carboplatin
Drug: alvocidib
Drug: topotecan hydrochloride
Drug: cytarabine
Drug: sirolimus
Drug: etoposide
First Posted Date
2008-03-12
Last Posted Date
2015-07-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
92
Registration Number
NCT00634244
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 17 locations

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Phase 3
Active, not recruiting
Conditions
Lung Cancer
Interventions
Radiation: Standard Radiation Dose Therapy
Drug: cisplatin
Drug: etoposide
Radiation: High Radiation Dose Therapy
Drug: carboplatin
First Posted Date
2008-03-11
Last Posted Date
2023-06-12
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
731
Registration Number
NCT00632853
Locations
🇺🇸

Saint Mary Corwin Medical Center, Pueblo, Colorado, United States

🇺🇸

NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States

🇺🇸

Illinois CancerCare-Princeton, Princeton, Illinois, United States

and more 928 locations

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

First Posted Date
2008-03-11
Last Posted Date
2020-04-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
21
Registration Number
NCT00632827
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Phase 2
Terminated
Conditions
Leukemia
Interventions
Biological: sargramostim
Drug: busulfan
Drug: cyclophosphamide
Drug: dexamethasone
Drug: etoposide
Procedure: bone marrow transplantation
Procedure: hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
First Posted Date
2008-03-07
Last Posted Date
2024-01-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
12
Registration Number
NCT00630565
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2
Completed
Conditions
Prostate Cancer
First Posted Date
2008-03-03
Last Posted Date
2011-05-16
Lead Sponsor
Groupe D'Etude des Tumeurs Uro-Genitales
Target Recruit Count
90
Registration Number
NCT00627354
Locations
🇫🇷

Centre Regional Francois Baclesse, Caen, France

MT2004-30: Tomotherapy for Solid Tumors

Phase 1
Terminated
Conditions
Sarcoma
Brain and Central Nervous System Tumors
Kidney Cancer
Liver Cancer
Retinoblastoma
Interventions
Biological: filgrastim
Drug: busulfan
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Drug: thiotepa
Procedure: stem cell transplantation
Radiation: tomotherapy
Radiation: total marrow irradiation
Drug: Mesna
Radiation: Whole lung radiation
First Posted Date
2008-02-25
Last Posted Date
2017-12-05
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
23
Registration Number
NCT00623077
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy